4//SEC Filing
Schorno Dean L 4
Accession 0000905148-24-002511
CIK 0001034842other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 8:33 PM ET
Size
5.9 KB
Accession
0000905148-24-002511
Insider Transaction Report
Form 4
Schorno Dean L
EVP & Chief Financial Officer
Transactions
- Award
Employee Stock Option (right to buy)
2024-08-30+10,000→ 10,000 totalExercise: $24.20Exp: 2030-02-06→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met.
- [F2]The option was fully vested on August 30, 2024, the date the determination was made that the performance metric had been met.
Documents
Issuer
RIGEL PHARMACEUTICALS INC
CIK 0001034842
Entity typeother
Related Parties
1- filerCIK 0001509688
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 8:33 PM ET
- Size
- 5.9 KB